High frequencies of PMN-MDSCs are associated with low suppressive capacity in advanced stages of HIV-1 infection by Grützner, Eva M. et al.
RESEARCH Open Access
High frequencies of PMN-MDSCs are
associated with low suppressive capacity in
advanced stages of HIV-1 infection
Eva M. Grützner1,2, Ashley Neizert1, Renate Stirner1,2, Raffaele Conca3, Immanuel Andrä4, Lisa Wolff5,2,
Matthias Schiemann4, Lesca M. Holdt6, Christoph Klein3, Johannes R. Bogner1,2 and Rika Draenert1,2*
Abstract
Background: Polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) are an immature cell type that
inhibits the effector functions of T lymphocytes in chronic HIV infection. A well-known immunological feature
of the disease course is the development of immune exhaustion, which is correlated with excessive immune
activation in late-stage disease. Here, we hypothesized that immune exhaustion would also affect PMN-MDSCs in
late-stage HIV-1 infection.
Methods: We evaluated untreated chronically HIV-infected patients (progressors, n = 10) and control groups
(controllers, patients with non-small cell lung carcinoma and healthy controls, n = 16) with regard to levels of PMN-
MDSCs and their inhibitory potential. Additionally, we studied CD8 T cell effector functions (interferon-gamma, TNF
alpha, IL-2 and CD107) and parameters of CD8 T cell activation (CD38 and HLA-DR) and exhaustion (PD-1 and LAG-
3) by flow cytometry. Plasma inflammation markers analyzed here were IL-6, IL-8, soluble CD14, highly sensitive CRP,
and cystatin C.
Results: Coincubation experiments with isolated PMN-MDSCs led to a significant inhibition of CD8 T cell
proliferation (p < 0.0001), with a significant correlation between PMN-MDSC frequency and suppressive capacity: the
higher the frequency of PMN-MDSCs was, the lower the suppressive capacity (rho = 0.51, p = 0.0082). Stratifying all
study subjects into subgroups with PMN-MDSC frequencies above or below 2.5% resulted in a significantly
increased suppressive capacity in patients with frequencies below 2.5% (p = 0.021). While there was no correlation
with the cellular activation markers CD38 and HLA-DR, high IL-8 levels were significantly associated with high
PMN-MDSC frequencies (rho = 0.52, p = 0.0074) and low suppressive capacity (rho = 0.47, p = 0.019).
Conclusions: In this study, we demonstrate for the first time that PMN-MDSCs show limited effector functions in
advanced disease stages of HIV infection. The hyperactive immune state is associated with this loss of function.
However, we show an association with the proinflammatory cytokine IL-8, which is an important factor for the
migration and adhesion of polymorphonuclear cells.
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Background
Human myeloid-derived suppressor cells (MDSCs)
represent a heterogeneous group of immature cells that
evolve from myeloid progenitor cells and have an im-
munosuppressive function. Two major subsets of
MDSCs have been described: polymorphonuclear
(PMN)- and monocytic (M)-MDSCs [1]. PMN-MDSCs,
which are the focus of this study, are precursor cells of
granulocytes and are therefore expected to resemble this
cell type with regard to migration, adhesion and mecha-
nisms of action [1, 2]. The immunosuppressive potential
of PMN-MDSCs has been described in an oncology
context [1–7] and more recently in infectious diseases
[8–11]. PMN-MDSCs were shown to accumulate in
chronic HIV infection [8, 12]. Significantly higher num-
bers of PMN-MDSCs have been found in untreated
patients with progressive HIV infection (progressors =
PR) than in HIV-uninfected/healthy controls (HC), HIV
controllers (CO) or antiretroviral-treated patients [8, 13].
PMN-MDSC frequencies also correlate with markers of
disease progression, namely, CD4 T cell count and viral
load. In addition, the suppressive potential of these cells
has mostly been shown with regard to T cell function in
chronic progressive HIV infection.
Via their immunoinhibitory actions, MDSCs are pre-
sumed to contribute to T cell exhaustion, which is a
well-known hallmark of chronic HIV infection. Immune
exhaustion in HIV infection has been the focus of in-
tense research efforts over the past several years. During
untreated HIV disease, the polyfunctionality of CD8 T
cells declines and therefore their ability to proliferate
and to produce the cytokines CD107a, IL-2, TNF alpha
and interferon-gamma diminishes. Consequently, the
immune system loses the ability to control the infection,
and the disease progresses towards the AIDS stage. Im-
mune exhaustion has been demonstrated for several
parts of the immune system; however, it is not known if
this exhaustion also affects MDSCs [14–22].
Immune exhaustion in HIV disease is inseparably
linked to excessive immune activation, which also corre-
lates with disease progression [23, 24]. This excessive
activation contributes to high T cell turnover and can be
measured by cellular and soluble factors, e.g., the expres-
sion of CD38 and HLA-DR on T cells. Additionally, the
elevated plasma levels of proinflammatory cytokines
such as interferon-gamma type 1, IL-6, IL-8 and TNF
alpha and the increased serum markers of inflammation
CRP, cystatin C and sCD14 are indicative of intense im-
mune activation in HIV infection [25, 26]. IL-8, also
called CXCL8, is a member of the chemokine family and
interacts with the cellular receptors CXCR1 and CXCR2.
IL-8 is an important factor for the migration and activa-
tion of polymorphonuclear cells, which include PMN-
MDSCs. In the context of HIV infection, IL-8 has been
studied extensively and has been shown to be a marker
of immune activation in HIV disease with relevance to
polymorphonuclear cells [27–35].
In the present study, we evaluated the suppressive cap-
acity of human PMN-MDSCs in different disease stages
and entities and studied the association of suppressive
capacity with markers of immune activation (IL-8 among
others) and immune exhaustion, as well as with the ef-
fector functions of HIV-specific CD8 T cells.
Methods
Study subjects
Twenty-six individuals participated in the study after
signing informed consent. The study was approved by
the Institutional Review Board of the Ludwig-
Maximilian-Universität, Munich, Germany (project
number: 227–11). The study subjects were divided into
the following groups:
PR (progressors: untreated patients with chronic HIV
infection; n = 10): defined by a CD4 cell count less than
400/μl and a viral load (VL) greater than 10,000 copies/
ml. These patients were newly diagnosed and started
antiretroviral treatment directly after the study blood
draw. The median CD4 count was 80/μl (range 4–355/
μl), and the median VL was 276,802 copies/ml (range
2100 – 5,999,674 copies/ml).
CO (controllers: patients who had controlled the HIV
infection spontaneously in the absence of HAART for
more than 4 years; n = 5): defined by a CD4 cell count
above 500/μl and a VL below 2000 copies/ml (including
elite controllers (EC): patients with a VL below 40 cop-
ies/ml; n = 3). The median CD4 count was 923/μl (range
644–1085/μl), and the median VL was 40 copies/ml
(range 40–1940 copies/ml).
We included an exception to these definitions: PR 1
had a low CD4 cell count of 80 cells/μl, and therefore,
we accepted a low-level viremia of 2100 copies/ml.
BRO (n = 6): patients with advanced-stage non-small
cell lung carcinoma (NSCLC) before specific treatment;
disease stage III or IV; and HIV-uninfected.
HC (healthy controls; n = 5).
PBMCs (peripheral blood mononuclear cells) of add-
itional HIV-uninfected subjects were used as target cells
for proliferation assays. These volunteers also signed in-
formed consent.
The characteristics of the study subjects are summa-
rized in Table 1.
Blood processing
For cytokine staining, freshly obtained EDTA blood was
centrifuged, and the obtained plasma was frozen at −
80 °C. Then, PBMCs were isolated by Ficoll density
gradient centrifugation (Biocoll Separation Solution,
Biochrom, Germany). Frequencies of PMN-MDSCs were
Grützner et al. Translational Medicine Communications             (2020) 5:1 Page 2 of 11
determined on fresh PBMCs directly (≤2 h after blood
draw). For isolation of CD66b+ cells, PBMCs were puri-
fied by positive selection of CD66b cells using magnetic
microbeads (EasySep human whole blood CD66b posi-
tive selection kit, StemCell Technologies, France) ac-
cording to the manufacturer’s instructions. To increase
purity, preselected CD66b+ cells were flow-sorted gating
on CD66b+/CD15+ on a FACS Aria (Becton Dickinson
GmbH, Heidelberg) for HIV-uninfected cells (BRO, HC)
and on a MoFlo Astrios EQ (Beckman Coulter Life
Sciences, Indianapolis, IN, USA) for HIV-infected sam-
ples (PR, CO). This procedure revealed high purities of
PMN-MDSCs (median 89%), even in the presence of ex-
tremely low PMN-MDSC frequencies among PMBCs.
PMN-MDSC-depleted PBMCs (hereafter called “PBMCs
depleted”) contained a median of 0.08% CD66b+ cells.
CD8 T cell proliferation assay
CD8 T cell proliferation was evaluated by CFSE staining
(5,6-carboxyfluorescein diacetate, succinimidyl ester,
Sigma Aldrich, Germany) as described previously [36].
Briefly, PBMCs of HIV-uninfected target cells were la-
beled with CFSE and coincubated with either unstained
target cells (negative and positive control) or with ef-
fector cells of study subjects (CD66+ cells (PMN-
MDSCs) and CD66-depleted PBMCs (PBMCs depleted),
respectively). The ratio of effector to target cells was 2:1.
For nonspecific stimulation of all cells (except cells of
negative control), PHA (phytohemagglutinin, 1.25 μg/ml,
Sigma Aldrich, Germany) was used. The negative control
consisted of unstimulated cells. After culturing at 37 °C
and 5% CO2 for 72 h, target cells were stained extracel-
lularly with CD8-PerCP (Biolegend) and analyzed on a
FACSCalibur (BD, Germany) to determine CD8 T cell
proliferation (for gating strategy see Additional file 1).
We defined the suppressive capacity as a readout for
the functionality of MDSCs and used the following
formula: Proliferation PMN−MDSCs−Proliferation}PBMCs depleted}Proliferation}PBMCs depleted} 100. A
negative value for the suppressive capacity demonstrates
the ability of PMN-MDSCs to inhibit CD8 T cell
proliferation.
Peptides
Two pools of overlapping synthetic peptides correspond-
ing to the HIV proteins Gag and Nef/Rev/Tat were used
for HIV-specific stimulation (final concentration 2 μg/ml
per peptide). Peptides were 15–20 amino acids long with
an overlap of 5–10 amino acids, corresponding to Gag
HIV-1 SF-2, to Nef HIV-1 18 BRU, to Tat HIV-1 LAI
and to Rev. HIV-1 LAI, and had a purity of ≥70%
(NIBSC, England).
Phenotyping and flow cytometric analysis
Extracellular staining of fresh PBMCs with fluorescent
antibodies was performed as described previously [8]
to determine the frequencies of PMN-MDSCs. For
analysis of immune activation, immune exhaustion
and polyfunctions of CD8 T cells, frozen PBMCs
were thawed, cultured at 37 °C and 5% CO2 overnight
and phenotyped in two panels. For panel 1 (immune
activation, immune exhaustion), cells were extracellu-
larly stained [8]. For panel 2, cells were stimulated
with either Gag or Nef/Rev/Tat peptides or left un-
stimulated (negative control) in three tubes. CD107a-
FITC was directly added to each of the tubes, which
were cultured for 1 h at 37 °C and 5% CO2, after
which monensin (0.7 μl/106 cells, BD, Germany) and
brefeldin (10 μg/ml, Sigma Aldrich, Germany) were
added. After a total of 6 h of incubation, the cells
were extracellularly and intracellularly stained for
polyfunctions of CD8 T cells (according to [37, 38],
for gating strategy see Additional file 1).
The following antibodies were used: PMN-MDSCs:
CD11b-FITC, CD14-APC, CD15-PerCP/CD15-FITC,
CD66b-PE [39, 40]; immune activation/immune
exhaustion: CD8-Pacific blue, CD38-PE, HLA-DR-APC,
PD-1-FITC, LAG-3-PE/Cy7; and polyfunctionality:
CD8-Pacific blue, interferon-gamma-APC, IL-2-PE,
TNF alpha-PE/Cy7 and CD107a-FITC (all BioLegend,
USA, with the exception of CD107a-FITC: Becton
Dickinson GmbH, Germany).
PMN-MDSCs were analyzed on a FACSCalibur
(BD, Germany), and CD8 T cell surface markers with
the exception of proliferation were analyzed on a
FACSCanto II (BD, Germany). The analysis of data








PR (n = 10) 80 4–355 276,802 2100-5,999,674 2.37 0.23–14.41
CO (n = 5) 923 644–1085 40 < 40–1940 0.13 0.09–0.44
BRO (n = 6) n.s. n.s. n.a. n.a. 2.84 1.62–6.76
HC (n = 5) n.s. n.s. n.a. n.a. 0.48 0.11–1.85
PR progressors, CO controllers, BRO patients with advanced-stage non-small cell lung carcinoma (NSCLC): disease stage III and IV; HC healthy controls, n.s. not
specified, n.a. not applicable.
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was performed using FlowJo software 10.2 (TreeStar,
Inc. Ashland, OR, USA). The gating strategies of
PMN-MDSCs are described in Fig. 1e. For the statis-
tics, we indicated PMN-MDSCs as a percentage of
PBMCs in all subgroups because the numbers of
monocytes varied substantially in subjects with
chronic viral infections.
Cytokine staining
IL-6 was determined by electrochemiluminescence
immunoassay on a Cobas e411 (Roche, Mannheim,
Germany). For cystatin C and CRP analyses, particle-
enhanced turbidimetric immunoassays (PETIA) were
performed on a Cobas 8000 c702 and on a Cobas c311,
respectively (both Roche, Mannheim, Germany). IL-8
and soluble CD14 (sCD14) were analyzed using a human
IL-8/CXCL8 Quantikine ELISA Kit (D8000C) and a
human CD14 Quantikine ELISA Kit (DC140) (both
R&D Systems, Inc. USA) following the manufacturer’s
instructions.
Statistical analysis
The statistical analyses were performed using Graph-
Pad Prism version 5.0. In most cases, our data were
not normally distributed. Therefore, we only used
nonparametric tests. Comparisons between two
groups were performed with the Mann-Whitney U
test (level of significance p < 0.05), and comparisons
between more than two groups were first tested with
the Kruskal-Wallis test. If this was significant (p <
0.05), we also performed pairwise Mann-Whitney U
tests with Bonferroni-Correction for multiple testing.
Three pairwise comparisons were considered relevant
and were tested for each experiment as follows: PR
vs. CO, PR vs. HC, and PR vs. BRO. The corrected
level of significance, therefore, was p < 0.0167. In
Fig. 2e, the relevant two pairwise comparisons were <
2.5 PR vs >2.5 PR and <2.5 CO vs <2.5 PR with a
corrected level of significance of p < 0.025. Only tests
with significant results are indicated in the figures.
The Spearman rank test was used for correlation
analyses, and the Wilcoxon signed rank test was used
for paired comparisons (level of significance p < 0.05).
Results
The inhibitory potential of PMN-MDSCs varies widely in
patients with chronic HIV infection
As previously described [8], we found significantly in-
creased PMN-MDSC frequencies in PR versus CO (p =
0.0013), whereas the frequencies in PR were comparable
to those in BRO (p = 0.87) (Fig. 1a, e). Next, we evalu-
ated the functionality of the PMN-MDSCs. Again, analo-
gous to published data, we determined that CD8 T cell
proliferation was significantly inhibited by PMN-MDSCs
within all patients (p = 0.0001) as well as within PR pa-
tients (p = 0.0039) (Fig. 1b and c).
The suppressive capacity of all groups was similar
(p = 0.27, data not shown). However, we found that the
extent of the inhibition in PR patients was widespread.
The coincubation assay with PMN-MDSCs from the PR
patient with the lowest PMN-MDSC frequency of 0.23%
showed a strong inhibition of proliferation of CD8 T
cells by PMN-MDSCs (proliferation with PBMCs
depleted 65.90% vs. proliferation with PMN-MDSCs
26.60%, Fig. 1d). Surprisingly, in another patient with a
PMN-MDSC frequency of 8.05% (Fig. 1e), the prolifera-
tion of CD8 T cells was only slightly suppressed in the
presence of PMN-MDSCs compared to proliferation
with depleted PBMCs (52.84% vs. 55.48% proliferating
CD8 T cells) (Fig. 1f). This finding was confirmed by re-
peating the experiment several times.
The proliferation of CD8 T cells was significantly
inhibited by PMN-MDSCs in all patients, especially the
PR group. Interestingly, the ability of PMN-MDSCs to
inhibit proliferation varied substantially between PR
patients.
Inverse correlation of suppressive capacity of PMN-
MDSCs with their respective frequencies
To further evaluate the extent of the inhibitory func-
tion of PMN-MDSCs, we determined the suppressive
capacity in our cohort. Our previous observation was
confirmed in that we found a highly significant correl-
ation between the suppressive ca-pac-i-ty and PMN-
MDSC frequencies in individual patients (Fig. 2a;
rho = 0.51, p = 0.0082). However, this correlation was
to the effect that the higher the PMN-MDSC level
was, the weaker the inhibitory potential. This could be
shown for the entire cohort (Fig. 2a) as well as for the
PR group (Fig. 2b) and the combined subgroup of PR
and BRO (Additional file 2). In contrast, the correl-
ation of suppressive capacity and PMN-MDSC
frequencies was not significant in CO (Fig. 2c). Divid-
ing the patients into those with low PMN-MDSC
levels (< 2.5% of PBMCs) and those with high PMN-
MDSC frequencies (> 2.5% of PBMCs), revealed that
there was a significant difference in suppressive cap-
acity for the entire cohort (Fig. 2d; p = 0.021) and for
the selective PR group (Fig. 2e; p = 0.016). The cut-off
value of 2.5% was chosen because this was the median
PMN-MDSC frequency in the group of PR.
In conclusion, we found that the higher the PMN-
MDSC level in a patient is, the lower the suppressive
capacity of this immunoinhibitory cell type. Taken to-
gether, these findings suggest a state of immune exhaus-
tion in progressive HIV infection – the disease stage
with the highest PMN-MDSC frequencies.
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No correlation between the suppressive capacity of PMN-
MDSCs and the polyfunctionality of CD8 T cells or
immunoinhibitory signals
In HIV infection, immune exhaustion of CD8 T cells
is well described and reflected in the reduction of ef-
fector functions. We wanted to determine whether
the suppressive capacity of PMN-MDSCs is related
to the polyfunctionality of CD8 T cells. As PMN-
MDSCs are inhibitors of CD8 T cells, a strong in-
hibitory potential might be correlated with more
monofunctional CD8 T cells. For this purpose, we
stained for the four CD8 T cell effector functions
interferon-gamma, TNF alpha, IL-2 and CD107a as a
marker for degranulation after specific stimulation
Fig. 1 Frequencies, suppressive function and gating strategy of PMN-MDSCs. a Progressors (PR) showed significantly higher PMN-MDSC
frequencies than controllers (CO) (p = 0.0013), but there was no difference in the frequencies between PR patients and patients with lung
carcinoma (BRO) (p = 0.87). (b + c) Significantly decreased percentages of proliferating CD8 T cells after coincubation with PMN-MDSCs compared
to coincubation with PBMCs depleted in all patients (p = 0.0001) (b) and in PR (p = 0.0039) (c). The PBMCs depleted was set as 100%, and PMN-
MDSCs were calculated as percentages thereof. d Histograms of a proliferation assay with significant inhibition of CD8 T cell proliferation by
PMN-MDSCs in a sample from a patient with a low level of PMN-MDSCs (0.23%). e Representative dot plots and gating of PMN-MDSCs. Gating
here is demonstrated by a patient with a very high frequency of PMN-MDSCs (CD66+ CD15+ cells: 8.05%). The first gate (first panel) is placed on
the monocyte fraction in FSC and SSC. The main MDSC fraction is found in the population above the monocyte fraction (oval gate, first panel).
The second panel shows the CD11b+ and CD14− populations (upper left gate). PMN-MDSCs are defined as CD11b+ CD14− CD66b+ CD15+ and
are shown in the upper right gate of the third panel. Gating was performed according to Vollbrecht et al. [8] and Rieber et al. [37, 38]. f
Histograms of a proliferation assay with only minimal inhibition by PMN-MDSCs from the patient shown in (e). [PR: n = 10; CO: n = 5; HC: n = 5;
BRO: n = 6]
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with HIV peptides. We found no correlation in ei-
ther direction between the effector functions of HIV-
specific CD8 T cells and the suppressive capacity of
PMN-MDSCs (data not shown).
Next, we evaluated whether there is an association
between immunoinhibitory signals and the inhibitory
potential of PMN-MDSCs and chose PD-1 and LAG-3
for this purpose. As PMN-MDSCs have been shown to
use the PD-1/PD-L1 pathway, a strong suppressive cap-
acity of PMN-MDSCs could be related to high levels of
immune checkpoint molecules. There was, however, no
significant correlation between PD-1 or LAG-3 levels on
CD8 T cells with either the frequency of PMN-MDSCs
or the suppressive capacity of PMN-MDSCs in our co-
hort (data not shown).
Correlation of the suppressive capacity of PMN-MDSCs
with the proinflammatory cytokine IL-8
The immune exhaustion of certain cell types in progres-
sive HIV infection is associated with the well-described
hyperactive immune state. We hypothesized that the loss
of effector functions of PMN-MDSCs is also correlated
with this immune activation. Therefore, we determined
the CD38 and HLA-DR expression levels on CD8 T cells
as well as levels of markers of inflammation in plasma,
namely, cystatin c, highly sensitive CRP, IL-6, IL-8 and
sCD14.
As expected, the PR group exhibited significantly
higher proportions of CD38+ and HLA-DR+ CD8 T cells
compared to the CO and HC groups (Fig. 3a; p = 0.0031
and p = 0.0016, respectively). However, there was no
Fig. 2 Suppressive capacity of PMN-MDSCs and correlation with PMN-MDSC frequencies. (a + b + c) The suppressive capacity of PMN-MDSCs
correlates inversely and significantly with the PMN-MDSC frequencies in all subjects (rho = 0.51, p = 0.0082) (a) and in progressors (PR) (rho = 0.87,
p = 0.0022) (b), whereas there is no significant correlation in controllers (CO) (rho = 0.90, p = 0.083) (c). (d + e) The suppressive capacity is
significantly lower in subjects with PMN-MDSC frequencies above 2.5% compared to subjects with frequencies below 2.5% in all subjects (p =
0.021) (d) and in PR subjects (p = 0.016) (e). All controllers have PMN-MDSC frequencies below 2.5% (e). [all subjects: n = 26; PR: n = 10; CO: n = 5;
HC: n = 5; BRO: n = 6]
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correlation between the CD38+ and HLA-DR+ CD8 T
cells and either the PMN-MDSC frequencies or the
suppressive capacity (Fig. 3b and c). The same was true
for cystatin C, highly sensitive CRP, IL-6 and sCD14
(data not shown).
For plasma IL-8 levels, the Kruskal-Wallis test for the
comparison of more than two groups reached significance
(p = 0.037) which was driven by the high IL-8 levels in the
BRO group. However, plasma IL-8 levels failed to reach
statistical significance in the pairwise comparison between
PR vs. CO, HC or BRO (p > 0.098) (Fig. 4a). Interestingly,
we found a significant correlation between IL-8 levels and
PMN-MDSC frequencies and suppressive capacity (Fig. 4b:
rho = 0.52, p = 0.0074 and Fig. 4c: rho = 0.47, p = 0.019).
Fig. 3 Immune activation and correlation of CD8+ CD38+ HLA-DR+ cells with frequencies and suppressive capacity of PMN-MDSCs. a Frequencies
of CD8 T cells expressing CD38 and HLA-DR were significantly higher in progressors (PR) than in controllers (CO) (p = 0.0031) and healthy controls
(p = 0.0016). b CD8 T cells expressing CD38 and HLA-DR do not correlate with PMN-MDSC frequencies (rho = 0.085, p = 0.71) (b) and suppressive
capacity (rho = − 0.25, p = 0.27) (c) in all subjects. d Representative dot plots and gating strategies of activated CD8 T cells. The first panel shows
the lymphocyte population. The CD8 positive cells are gated in the second panel (rectangular gate). Afterwards, CD8 T cells were gated on the
markers HLA-DR and CD38. [all subjects: n = 22; PR: n = 8; CO: n = 5; HC: n = 5; BRO: n = 4]
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The higher the IL-8 levels in a patient are, the weaker the
PMN-MDSCs’ suppressive capacity.
In conclusion, the loss of the inhibitory potential of
PMN-MDSCs is associated with an increase in the levels
of the proinflammatory cytokine IL-8, which is an im-
portant cytokine for the migration and adhesion of poly-
morphonuclear cells.
Discussion
To the best of our knowledge, in this study, we describe
for the first time that PMN-MDSCs become exhausted
in advanced HIV disease. Our data show a diminished
suppressive capacity of these cells in patients with far
advanced disease status and a high frequency of PMN-
MDSCs. This limitation of suppressive capacity was not
correlated with markers of immunoinhibition (e.g., PD-
1) but to immune activation, namely, the proinflamma-
tory cytokine IL-8.
Inhibition of CD8 T cell function by PMN-MDSCs is
well described to occur not only with malignant diseases
but also in HIV infection [2, 4–6, 8, 9, 41–43]. In our
cohort, we observed significant inhibition of CD8 T cell
proliferation by purified PMN-MDSCs, and thus we con-
firmed data previously published by our group and by
others [8, 43]. Interestingly, we found differences in PR
patients regarding the potential to suppress T cell
function. First, one AIDS patient with an exceptionally
high PMN-MDSC frequency showed an almost complete
lack of inhibition of T cell proliferation in repeated
experiments. Testing a cohort of patients with advanced
disease, we confirmed the results that the inhibitory
effect of PMN-MDSCs declined with increasing PMN-
MDSC frequencies. This finding was not only true for
chronic HIV infection but also for late-stage lung cancer,
as shown in our group of patients with bronchial
carcinoma, which we used as positive controls (see
Additional file 2). Thus far, the exhaustion of PMN-
MDSCs in the disease course has not been described for
either the cancer setting or chronic viral infections.
Immune exhaustion during progressive disease, how-
ever, is a well-known fact in HIV-specific CD8 T cells
[14, 44–47]. In a typical succession, these cells lose ef-
fector functions, starting with the loss of the capability
to produce IL-2 and TNF alpha. Interferon-gamma pro-
duction is one of the last remaining functions [14, 45,
48, 49]. The progressive exhaustion of CD8 T cells
(among other immune cells) results in an increased viral
load and disease progression in chronic, untreated HIV
infection [14]. In addition to CD8 T cells, the exhaustion
of other immune cells such as CD4 T cells, B cells and
NK cells has been reported in progressive HIV infection
[15–19, 22, 49]. Therefore, the principle of immune
Fig. 4 Plasma levels of IL-8 and their correlation with the frequencies and suppressive capacity of PMN-MDSCs. a Plasma IL-8 levels were
comparable in progressors (PR), controllers (CO), healthy controls (HC) and patients with lung cancer (BRO) (p > 0.098); however, the Kruskal-Wallis
test for the comparisons of more than two groups reached significance (p = 0.037). b IL-8 levels correlated directly and significantly with
frequencies (rho = 0.52, p = 0.0074) (b) and suppressive capacity (rho = 0.47, p = 0.019) (c) of PMN-MDSCs in all subjects. [PR: n = 10, CO: n = 5, HC:
n = 5, BRO: n = 5, all subjects: n = 25]
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exhaustion seems to hold true for a wide range of im-
mune cells – now also including PMN-MDSCs.
We further wanted to test whether the differing sup-
pressive capacity of PMN-MDSCs has varying influences
on T cell effector functions. If so, a strong suppressive
capacity would be found in patients without diverse CD8
T cell cytokine production. However, we were not able
to demonstrate such a relationship in our experimental
setting. There also does not seem to be any evidence in
the literature showing such an association. Exhausted T
cells in HIV infection express elevated markers of immu-
noinhibition, e.g., PD-1 or LAG-3 [20, 50–56]. It is ac-
cepted that the loss of T cell function is induced by
these inhibitory pathways, which is why they are also
called immune checkpoint molecules [16, 50–52]. There
is evidence that MDSCs use the PD-1/PD-L1 pathway
for their suppressive function with regard to T cell pro-
liferation [57, 58]. Therefore, we hypothesized that a
strong suppressive capacity of PMN-MDSCs involves
high PD-1 expression on T cells. In our study, we were
not able to prove the hypothesis of a correlation between
the suppressive capacity of PMN-MDSCs and the level
of these well-described markers of immune exhaustion
on T cells.
However, the level and functionality of PMN-MDSCs
were distinctly associated with immune activation. Not-
ably, we observed a correlation between the frequency
and suppressive capacity of PMN-MDSCs and plasma
levels of the proinflammatory cytokine IL-8. Increased
IL-8 levels were related to increased PMN-MDSC fre-
quencies and reduced suppressive capacity. Hence, ex-
cessive immune activation in progressive HIV infection
is also associated with decreased PMN-MDSC function.
In our study, there was no correlation between the
suppressive capacity of PMN-MDSCs and the expression
of CD38 and/or HLA-DR on T cells. However, CD38
and HLA-DR are activation markers of the T lympho-
cyte pathway. PMN-MDSCs, on the other hand, are
closely related to granulocytes, which are part of a differ-
ent developmental strand. IL-8 is an important cytokine
for this cell type. The CXC chemokine IL-8 attracts neu-
trophils to sites of inflammation [28, 59–62]. More re-
cently, it was reported that IL-8 also attracts MDSCs
(PMN-MDSCs as well as M-MDSCs) isolated from
cancer patients in transwell migration assays. The au-
thors showed the expression of the IL-8 receptors
CXCR1 and CXCR2 on the surface of PMN-MDSCs
[63]. Interestingly, we were also able to observe signifi-
cantly higher expression levels of CXCR1 and CXCR2
on PMN-MDSCs in PR compared to healthy controls
(preliminary unpublished data of our group).
Increased IL-8 plasma levels in cancer patients predict
increased disease severity [64–67]. Consistently, published
data in HIV infection has shown that increased IL-8 levels
correlate with mortality, reduced CD4 cell count and in-
creased viral load [28–33]. In a study of HIV/tuberculosis
coinfected patients, a direct association of plasma IL-8
levels was found with frequencies of granulocytes and
their capacity to migrate in response to IL-8. Moreover,
markedly increased IL-8 levels were observed in lymphoid
tissue in patients with progressive HIV infection [27].
Based on the above-mentioned data in cancer and
HIV, it is tempting to suggest that in progressive HIV
infection, PMN-MDSCs migrate to major sites of HIV
replication, namely, the lymphoid tissue, induced by
elevated levels of IL-8. As PMN-MDSCs are nonfunc-
tional in advanced disease, increased levels of IL-8
should attract more PMN-MDSCs. However, our data
reflect the levels of IL-8 and MDSCs in human blood
only and are limited with regard to lymphatic tissue.
The latter remains to be elucidated in future studies.
In conclusion, our study is the first to show a limita-
tion of functionality of PMN-MDSCs in advanced HIV
disease. Our results support a close relationship between
this limitation of suppressive capacity of MDSCs and im-
mune activation. Hence, the results of this study unravel
another component of HIV immunopathogenesis.
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